Roche (RHHBY) said the significantly lower demand for COVID-19 tests led to a decrease in first quarter Group sales of 3% at constant exchange rates and a decline of 7% in Swiss francs. Excluding this effect, Group sales grow 8%. Pharmaceuticals Division sales were up 9%. Diagnostics Division base business rose 4%. The company noted that it saw strong growth in both divisions' base business. Looking forward, Roche confirmed its outlook for 2023.
from RTT - Earnings https://ift.tt/EJHB6Wj
via IFTTT
No comments:
Post a Comment